Polypharmacy: Definition, Epidemiology, Consequences and Solutions

Increasing multimorbidity in an ageing population has led to a rise in the prevalence of polypharmacy throughout the developed world. In many cases, polypharmacy is justified and reflects the increased range of therapeutic options modern medicine can offer. However, ageing is associated with physiological changes affecting drug pharmacokinetics and pharmacodynamics. Complex combinations of multiple medications in multimorbid older adults lead to drug–drug interactions, drug–disease interactions and an increased risk of adverse outcomes. It is important to differentiate between appropriate and inappropriate polypharmacy; the latter is associated with geriatric syndromes including falls, immobility, fractures, cognitive impairment and frailty as well as excess hospitalisation and mortality. Inappropriate polypharmacy is also associated with prescribing errors and non-adherence and represents a major avoidable economic cost to society.

By addressing this problem, prescribers can reduce an older person’s risk of adverse drug events, reduce medication burden, enhance the treatment of comorbidities and decrease costs for both the patient individually and the society generally. Medication review is a key component of comprehensive geriatric assessment and should follow the same systematic, holistic, multidisciplinary approach whilst simultaneously taking account of the patient’s wishes. Tools such as STOPP/START can identify potentially inappropriate medications that should be discontinued or medications that are likely to provide benefit to the patient and should be initiated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic €32.70 /Month

Buy Now

Price includes VAT (France)

eBook EUR 117.69 Price includes VAT (France)

Softcover Book EUR 116.04 Price includes VAT (France)

Hardcover Book EUR 158.24 Price includes VAT (France)

Tax calculation will be finalised at checkout

Purchases are for personal use only

References

  1. Corselli-Nordblad L, Strandell H. Ageing Europe—Looking at the lives of older people in the EU 2020 edition. Luxembourg: Eurostat; 2020. https://doi.org/10.2785/628105. BookGoogle Scholar
  2. United Nations Department of Economic and Social Affairs Population Division. The world population ageing 2020 highlights: living arrangements of older persons. New York: United Nations; 2020. Google Scholar
  3. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17:1185–96. https://doi.org/10.1080/14740338.2018.1546841. ArticlePubMedGoogle Scholar
  4. Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol. 2015;11:491–508. PubMedGoogle Scholar
  5. Maher D, Ailabouni N, Mangoni AA, Wiese MD, Reeve E. Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opin Drug Metab Toxicol. 2020;17:41–52. https://doi.org/10.1080/17425255.2021.1839413. ArticleCASPubMedGoogle Scholar
  6. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77. PubMedGoogle Scholar
  7. Scottish Government Polypharmacy Model of Care Group. Polypharmacy guidance, realistic prescribing. 3rd ed. Edinburgh: NHS; 2018. Google Scholar
  8. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999 to 2012. JAMA. 2015;314:1818–30. CASPubMedPubMed CentralGoogle Scholar
  9. Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;11:2042098620933741. https://doi.org/10.1177/2042098620933741. ArticlePubMedPubMed CentralGoogle Scholar
  10. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015;5:e008656. PubMedPubMed CentralGoogle Scholar
  11. Midão L, Giardini A, Menditto E, et al. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr. 2018;78:213–20. PubMedGoogle Scholar
  12. Wastesson JW, Fastbom J, Johnell K. Expanding the proportion of life with polypharmacy in Sweden: 2006–2013. J Am Med Dir Assoc. 2016;17:957–8. PubMedGoogle Scholar
  13. Hernández-Rodríguez MÁ, Sempere-Verdú E, Vicens-Caldentey C, et al. Evolution of polypharmacy in a Spanish population (2005–2015): a database study. Pharmacoepidemiol Drug Saf. 2020;29:433–43. PubMedGoogle Scholar
  14. Lukačišinová A, Fialová D, Peel NM, et al. The prevalence and prescribing patterns of benzodiazepines and Z-drugs in older nursing home residents in different European countries and Israel: retrospective results from the EU SHELTER study. BMC Geriatr. 2021;211(21):1–16. Google Scholar
  15. Toepfer S, Bolbrinker J, König M, Steinhagen-Thiessen E, Kreutz R, Demuth I. Potentially inappropriate medication in older participants of the Berlin Aging Study II (BASE-II)—sex differences and associations with morbidity and medication use. PLoS One. 2019;14:e0226511. CASPubMedPubMed CentralGoogle Scholar
  16. Franchi C, Tettamanti M, Pasina L, Djignefa CD, Fortino I, Bortolotti A, Merlino L, Nobili A. Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-elderly project 2000–2010. Eur J Clin Pharmacol. 2014;70:437–43. CASPubMedGoogle Scholar
  17. Mair A, Fernandez-Llimos F, Alonso A, Harrison C, Hurding S, Kempen T, Kinnear M, Michael N, McIntosh J, Wilson M. Polypharmacy management by 2030: a patient safety challenge. 2nd ed. Coimbra: Simpathy; 2017. Google Scholar
  18. Kongkaew C, Hann M, Mandal J, Williams SD, Metcalfe D, Noyce PR, Ashcroft DM. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy. 2013;33:827–37. PubMedGoogle Scholar
  19. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6. CASPubMedPubMed CentralGoogle Scholar
  20. Weaving G, Batstone GF, Jones RG. Age and sex variation in serum albumin concentration: an observational study. Ann Clin Biochem. 2015;53:106–11. https://doi.org/10.1177/0004563215593561. ArticleCASPubMedGoogle Scholar
  21. Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009;120:419. PubMedPubMed CentralGoogle Scholar
  22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. CASPubMedGoogle Scholar
  23. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. PubMedPubMed CentralGoogle Scholar
  24. Johnell K, Klarin I. The relationship between number of drugs and potential drug–drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30:911–8. PubMedGoogle Scholar
  25. de Oliveira LM, Diel JD, Nunes A, Dal Pizzol TD. Prevalence of drug interactions in hospitalised elderly patients: a systematic review. Eur J Hosp Pharm. 2021;28:4–9. PubMedGoogle Scholar
  26. Danijea G, Kristina J. Clinical implications from drug–drug and drug–disease interactions in older people. Clin Exp Pharmacol Physiol. 2013;40:320–5. Google Scholar
  27. Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62:2261–72. PubMedPubMed CentralGoogle Scholar
  28. Laflamme L, Monárrez-Espino J, Johnell K, Elling B, Möller J. Type, number or both? A population-based matched case-control study on the risk of fall injuries among older people and number of medications beyond fall-inducing drugs. PLoS One. 2015;10(3):e0123390. https://doi.org/10.1371/JOURNAL.PONE.0123390. ArticlePubMedPubMed CentralGoogle Scholar
  29. Ambrose AF, Paul G, Hausdorff JM. Risk factors for falls among older adults: a review of the literature. Maturitas. 2013;75:51–61. PubMedGoogle Scholar
  30. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12:43. CASPubMedPubMed CentralGoogle Scholar
  31. Niikawa H, Okamura T, Ito K, Ura C, Miyamae F, Sakuma N, Ijuin M, Inagaki H, Sugiyama M, Awata S. Association between polypharmacy and cognitive impairment in an elderly Japanese population residing in an urban community. Geriatr Gerontol Int. 2017;17:1286–93. PubMedGoogle Scholar
  32. Rawle MJ, Cooper R, Kuh D, Richards M. Associations between polypharmacy and cognitive and physical capability: a British birth cohort study. J Am Geriatr Soc. 2018;66:916–23. PubMedPubMed CentralGoogle Scholar
  33. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, Coulton S, Katona C, Boustani MA, Brayne C. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc. 2011;59:1477–83. PubMedGoogle Scholar
  34. Welsh TJ, van der Wardt V, Ojo G, Gordon AL, Gladman JRF. Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging. 2018;356(35):523–38. Google Scholar
  35. Drake MJ, Nixon PM, Crew JP. Drug-induced bladder and urinary disorders. Drug Saf. 1998;19:45–55. CASPubMedGoogle Scholar
  36. Calderón-Larrañaga A, Poblador-Plou B, González-Rubio F, Gimeno-Feliu LA, Abad-Díez JM, Prados-Torres A. Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well? Br J Gen Pract. 2012;62:e821–6. PubMedPubMed CentralGoogle Scholar
  37. Aitken M, Gorokhovich L. Advancing the responsible use of medicines: applying levers for change. SSRN Electron J. 2012;2012:2222541. https://doi.org/10.2139/SSRN.2222541. ArticleGoogle Scholar
  38. Kempen TGH, Bertilsson M, Hadziosmanovic N, Lindner K-J, Melhus H, Nielsen EI, Sulku J, Gillespie U. Effects of hospital-based comprehensive medication reviews including postdischarge follow-up on older patients’ use of health care: a cluster randomized clinical trial. JAMA Netw Open. 2021;4(4):e216303. https://doi.org/10.1001/JAMANETWORKOPEN.2021.6303. ArticlePubMedPubMed CentralGoogle Scholar
  39. Mair A, Wilson M, Dreischulte T. The polypharmacy programme in Scotland: realistic prescribing. Prescriber. 2019;30:10–6. Google Scholar
  40. Rochon PA, Petrovic M, Cherubini A, Onder G, O’Mahony D, Sternberg SA, Stall NM, Gurwitz JH. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. Lancet Health Longev. 2021;2:e290–300. Google Scholar
  41. Wheeler AJ, Scahill S, Hopcroft D, Stapleton H. Reducing medication errors at transitions of care is everyone’s business. Aust Prescr. 2018;41:73. PubMedPubMed CentralGoogle Scholar
  42. Gleason KM, McDaniel MR, Feinglass J, Baker DW, Lindquist L, Liss D, Noskin GA. Results of the medications at transitions and clinical handoffs (MATCH) study: an analysis of medication reconciliation errors and risk factors at hospital admission. J Gen Intern Med. 2010;25:441–7. PubMedPubMed CentralGoogle Scholar
  43. Rachel E. Non-adherence to medicines: not solved but solvable. J Health Serv Res Policy. 2009;14:58–61. Google Scholar
  44. Paul G, Cristin R, Stephen B, Julia K, Denis O. STOPP (screening tool of older person’s prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83. Google Scholar
  45. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8. PubMedGoogle Scholar
  46. O’Connor MN, O’Sullivan D, Gallagher PF, Eustace J, Byrne S, O’Mahony D. Prevention of hospital-acquired adverse drug reactions in older people using screening tool of older persons’ prescriptions and screening tool to alert to right treatment criteria: a cluster randomized controlled trial. J Am Geriatr Soc. 2016;64:1558–66. PubMedGoogle Scholar
  47. Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7:11. PubMedPubMed CentralGoogle Scholar
  48. Lavan AH, Gallagher P, Parsons C, O’Mahony D. STOPPFrail (screening tool of older persons prescriptions in frail adults with limited life expectancy): consensus validation. Age Ageing. 2017;46:600–7. PubMedGoogle Scholar
  49. Curtin D, Gallagher P, O’Mahony D. Deprescribing in older people approaching end-of-life: development and validation of STOPPFrail version 2. Age Ageing. 2021;50:465–71. PubMedGoogle Scholar

Author information

Authors and Affiliations

  1. Department of Geriatric Medicine, Cork University Hospital, Cork, Ireland Donal Fitzpatrick
  2. Department of Geriatric Medicine, Bon Secours Hospital, Cork, Ireland Paul F. Gallagher
  1. Donal Fitzpatrick
You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Geriatric, Geriatric Admissions and Aging Research Center, IRCCS INRCA, Ancona, Italy Antonio Cherubini
  2. Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia Arduino A. Mangoni
  3. Department of Medicine, and Department of Geriatric Medicine, Cork University Hospital, Cork, Ireland Denis O’Mahony
  4. Section of Geriatrics, Department of Internal Medicine and Paediatrics, Ghent University, Gent, Belgium Mirko Petrovic

Ethics declarations

The above chapter is, in its entirety, the work of the listed authors. It does not contain any third party material or any material under copyright.

Rights and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Cite this chapter

Fitzpatrick, D., Gallagher, P.F. (2023). Polypharmacy: Definition, Epidemiology, Consequences and Solutions. In: Cherubini, A., Mangoni, A.A., O’Mahony, D., Petrovic, M. (eds) Optimizing Pharmacotherapy in Older Patients. Practical Issues in Geriatrics. Springer, Cham. https://doi.org/10.1007/978-3-031-28061-0_2

Download citation

Share this chapter

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative